Clinical Trial Update: iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of iTTo in treatment-naive advanced gastric cancer and gastroesophageal junction adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• iTTo

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma | Phase 2 | Status: COMPLETED